Pubblicazioni Scientifiche

Le pubblicazioni scientifiche

I risultati di tutti gli studi condotti dalla FIL vengono presentati ai maggiori congressi nazionali e internazionali e inviati per la pubblicazione a riviste recensite.  

Di seguito l’elenco delle pubblicazioni direttamente derivanti da attività di ricerca FIL o lavori per cui la FIL ha fornito supporto scientifico ad altri promotori e partner di ricerca.

Cliccando sul titolo sarà possibile accedere direttamente a PubMed o ad altri portali in cui è possibile trovare gli abstract o, ove disponibili, i testi completi delle pubblicazioni.

 

Data Rivista Titolo Autori
2018 Giornale italiano di dermatologia e venereologia Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1. Trovato E, Pellegrino M, Filippi F, Mancini V, Pimpinelli N, Fimiani M.
2018 Blood Cancer J
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.
Ayed AO, Chiappella A, Pederson L, Laplant BR, Congiu AG, Gaidano G, Spina M, Re A, Cavallo F, Musuraca G, Macon WR, Witzig T, Vitolo U, Nowakowski GS
2018 JEADV Molecular genetic analyses of human endogenous retroviral elements belonging to the HERV-P and HERV-R family in primary cutaneous T-cell lymphomas. Bergallo M, Fava P, Galliano I, Novelli M, Montanari P, Daprà V, Rassu M, Quaglino P, Fierro MT.
2018 Giornale italiano di dermatologia e venereologia Verrucous mycosis fungoides. G Ital Dermatol Venereol. La Placa M, Alessandrini A, Agostinelli C, Pileri A
2018 Journal of clinical oncology Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron EmissionTomography/Computed Tomography Scan After Two ABVD Cycles: Long-TermResults of the GITIL/FIL HD 0607 Trial. Gallamini A1, Tarella C1, Viviani S1, Rossi A1, Patti C1, Mulé A1, Picardi M1, Romano A1, Cantonetti M1, La Nasa G1, Trentin L1, Bolis S1, Rapezzi D1, Battistini R1, Gottardi D1, Gavarotti P1, Corradini P1, Cimminiello M1, Schiavotto C1, Parvis G1, Zanotti R1, Gini G1, Ferreri AJM1, Viero P1, Miglino M1, Billio A1, Avigdor A1, Biggi A1, Fallanca F1, Ficola U1, Gregianin M1, Chiaravalloti A1, Prosperini G1, Bergesio F1, Chauvie S1, Pavoni C1, Gianni AM1, Rambaldi A1.
2018 JEADV Primary cutaneous small/medium-sized pleomorphic T-cell lymphoproliferative disorder shows a common vascular pattern at dermoscopy. J Eur Acad Dermatol Venereol Pileri A, Agostinelli C, Gaspari V, Leuzzi M, Sabattini E, Patrizi A, Savoia F
2018 Haematologica A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. Bomben R1, Ferrero S2,3, D’Agaro T4, Dal Bo M4, Re A5, Evangelista A6, Carella AM7, Zamò A8, Vitolo U3, Omedè P3, Rusconi C9, Arcaini L10, Rigacci L11, Luminari S12,13, Piccin A14, Liu D15, Wiestner A15, Gaidano G16, Cortelazzo S17, Ladetto M2,18, Gattei V4.
2018 Giornale italiano di dermatologia e venereologia Results of radiotherapy in minimal stage mycosis fungoides: a reappraisal after ten years. G Ital Dermatol Venereol Esposito L, Piccinno R, Marchese L, Berti E.
2018 JEADV Primary cutaneous peripheral T-cell lymphoma not otherwise specified: a rare and aggressive lymphoma. J Eur Acad Dermatol Venereol. Pileri A, Agostinelli C, Fuligni F, Broccoli A, Gunnella S, Sabattini E, Grandi V, Guglielmo A, Zinzani PL, Patrizi A, Pimpinelli N.
2018 Cancer immunology and immunotherapy The role of myeloid derived suppressor cells in mycosis fungoides. Cancer Immunol Immunother Pileri A, Agostinelli C, Quaglino P, Patrizi A, Pimpinelli N.
2018 Giornale italiano di dermatologia e venereologia Alopecia areata-like mycosis fungoides: lions for lambs. G Ital Dermatol Venereol. Pileri A, Agostinelli C, Bruni F, Grandi V, Alessandrini A, Pimpinelli N, Piraccini BM.
2018 European Journal of Cancer Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. Scarisbrick JJ, Hodak E, Bagot M, Stranzenbach R, Stadler R, Ortiz-Romero PL, Papadavid E, Evison F, Knobler R, Quaglino P, Vermeer MH.
2018 European Journal of Cancer Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D.
2018 Leukemia & lymphoma. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. Zaja F1, Salvi F2, Rossi M3, Sabattini E4, Evangelista A4, Ciccone G5, Angelucci E6, Gaidano G7, Zanni M7, Ladetto M2, Chiappella A8, Vitolo U8, Zinzani PL9, Califano C10, Tucci A11, Patti C12, Pileri SA13, Lenti V14, Piccaluga PP3, Cavallo F15, Volpetti S16, Perali G16, Assouline S17, Mann KK18, Morin R19, Alcaide M19, Bushell K19, Fanin R1, Levis A14.
2018 Oncotarget Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, Volpetti S, Ferrero S, Spina F, Pisani F, Merli M, Visco C, Paolini R, Zilioli VR, Baldini L, Di Renzo N, Tosi P, Cascavilla N, Molica S, Ilariucci F, Rigolin GM, D’Alò F, Vanazzi A, Santambrogio E, Marasca R, Mastrullo L, Castellino C, Desabbata G, Scortechini I, Trentin L, Morello L, Argnani L, Zinzani PL.
2018 Oncologist Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL
2018 Haematologica Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi (FIL) Sergio Storti, Michele Spina, Emanuela Anna Pesce, Flavia Salvi, Michele Merli, Alessia Ruffini, Giuseppina Cabras, Annalisa Chiappella, Emanuele Angelucci, Alberto Fabbri, Anna Marina Liberati, Monica Tani, Gerardo Musuraca, Annalia Molinari, Maria Pia Petrilli, Carmela Palladino, Rosanna Ciancia, Andrea Ferrario, Cristiana Gasbarrino, Federico Monaco, Vincenzo Fraticelli, Annalisa De Vellis, Francesco Merli and Stefano Luminari
2018 Biol Blood Marrow Transplant A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi Olivieri J1, Mosna F2, Pelosini M3, Fama A4, Rattotti S5, Giannoccaro M6, Carli G7, Tisi MC7, Ferrero S8, Sgherza N9, Mazzone AM10, Marino D11, Calimeri T12, Loseto G13, Saraceni F14, Tomei G15, Sica S16, Perali G17, Codeluppi K4, Billio A2, Olivieri A18, Orciuolo E3, Matera R6, Stefani PM19, Borghero C7, Ghione P8, Cascavilla N9, Lanza F14, Chiusolo P16, Finotto S11, Federici I18, Gherlinzoni F19, Centurioni R20, Fanin R21, Zaja F21; Fondazione Italiana LinfomiPostgraduate Master Course.
2018 Anticancer Research DNA from Human Polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in Cutaneous T-cell Lymphomas Bergallo M, Daprà V, Fava P, Ponti R, Calvi C, Montanari P, Novelli M, Quaglino P, Galliano I, Fierro MT.
2018 Ann Oncol Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome For Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled On Randomized Clinical Trials. Maurer MJ,Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B.
2018 Lancet Haematol Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Federico M1, Caballero Barrigón MD2, Marcheselli L3, Tarantino V4, Manni M4, Sarkozy C5, Alonso-Álvarez S6, Wondergem M7, Cartron G8, Lopez-Guillermo A9, Issa D10, Morschhauser F11, Alcoceba M2, Kimby E12, Rusconi C13, Chamuleau M7, Holte H14, Lockmer S12, Montoto S15, Gomes da Silva M16, Aurer I17, Zucca E18, Paszkiewicz-Kozik E19, Minoia C20, Skrypets T4, Blaker YN14, Salles G5, Coiffier B5; Aristotle Consortium.
2018 British journal of haematology. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. Avivi I1, Arcaini L2, Ferretti VV3, Boumendil A4, Finel H4, Milone G5, Zaja F6, Liliana D7, Musso M8, Didier B9, Bachy E10, Wattad M11, Nicolas-Virelizier E12, Gramatzki M13,14, Bourhis JH15, Caillot D16, Haenel A17, Held G18,19, Thieblemont C20, Jindra P21, Pohlreich D22, Guilhot F23, Kroschinsky F24, Wahlin B25, Scheid C26, Ifrah N27, Berthou C28, Dreger P4,29, Montoto S30, Conconi A31.
2018 Annals of Oncology Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol. Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.
2018 J Clin Oncol.
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR.
2018 European Journal of Cancer Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. Scarisbrick JJ, Hodak E, Bagot M, Stranzenbach R, Stadler R, Ortiz-Romero PL, Papadavid E, Knobler R, Quaglino P, Vermeer M
2018 American journal of hematology Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma. Tisi MC, Paolini R, Piazza F, Ravelli E, Tecchio C, Sartori R, Famengo B, D’Amore ESG, Carli G, Perbellini O, Di Bona E, Ruggeri M, Visco C.
2018 Modern Pathology Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. Mod Pathol. Di Napoli A, De Cecco L, Piccaluga PP, Navari M, Cancila V, Cippitelli C, Pepe G, Lopez G, Monardo F, Bianchi A, D’Amore ESG, Gianelli U, Facchetti F, Berti E, Bhagat G.
2018 British journal of Dermatology The PROCLIPI international registry of early stage Mycosis Fungoides identifies substantial diagnostic delay in most patients Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R.
2018 Giornale italiano di dermatologia e venereologia Italian Lymphoma Foundation. Real-life use of phototherapy in early-stage mycosis fungoides from the Cutaneous Lymphoma Commission of the Italian Lymphoma Foundation: results of a web-based survey. G Ital Dermatol Venereol. Grandi V, Fava P, Rupoli S, Alberti Violetti S, Canafoglia L, Berti E, Quaglino P, Pimpinelli N
2018 JEADV Standardization of regimens in Narrowband UVB and PUVA in early stage mycosis fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas. J Eur Acad Dermatol Venereol. Grandi V, Fava P, Rupoli S, Alberti Violetti S, Canafoglia L, Quaglino P, Berti E, Pimpinelli N; Cutaneous Lymphoma Task Force (Commissione Linfomi Cutanei) of Lymphoma Italian Foundation (Fondazione Italiana Linfomi, FIL).
2017 Critical reviews in oncology/hematology Primary mediastinal large B-cell lymphoma. Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM
2017 Expert review of hematology Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? Di Rocco A, De Angelis F, Ansuinelli M, Foà R, Martelli M
2017 Journal of clinical oncology Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisonein Previously Untreated Diffuse Large B-Cell Lymphoma. Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH.
2017 British journal of haematology Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri AJM, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Giovanella L, Zucca E, Johnson PWM.
2017 The Lancet Oncology Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D’Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.
2017 British journal of haematology Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. Cascione L., Rinaldi A., Chiappella A., Kwee I., Ciccone G., Altenbuchinger M., Kohler C., Vitolo U., Inghirami G., Bertoni F.
2017 Annals of hematology Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography. Puccini B, Nassi L, Minoia C, Volpetti S, Ciancia R, Riccomagno PC, Di Rocco A, Mulè A, Toldo C, Sassone MC, Guariglia R, Filì C, Finolezzi E, Falorio S, Zanon S, Furlan A, Doa G, Zaja F
2017 Journal of clinical oncology Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C.
2017 Journal of clinical oncology Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J.
2017 Hematological oncology Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. Luminari S, Viel E, Ferreri AJM, Zaja F, Chimienti E, Musuraca G, Tucci A, Balzarotti M, Tani M, Salvi F, Pesce EA, Ferrari A, Liberati AM, Spadea A, Marino D, Bruno-Ventre M, Volpetti S, Bottelli C, Ravaioli E, Merli F, Spina M.
2017 Haematologica Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R.
2017 Thrombosis and haemostasis Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F, Monaco F, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Visco C, Calabrese M, Limberti G, Levis A, Contino L, Ciccone G, Ladetto M.
2017 Blood Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Zinzani PL., Pellegrini C., Chiappella A., Di Rocco A., Salvi F., Cabras MG., Argnani L., Stefoni V.
2017 Thrombosis research PO-03 – Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). Santi RM, Ceccarelli M, Catania G, Monagheddu C, Evangelista A, Bernocco E, Monaco F, Federico M, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Calabrese M, Levis A, Visco C, Contino L, Ciccone G, Ladetto M.
2017 The Lancet Haematology Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, Di Rocco A, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldero G, Nonis A, Scarfò L, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M.
2017 International journal of radiation oncology, biology, physics Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. Ceriani L., Martelli M., Gospodarowicz MK., Ricardi U., Ferreri AJ., Chiappella A., Stelitano C., Balzarotti M., Cabrera ME., Cunningham D., Guarini A., Zinzani PL., Giovanella L., Johnson PW., Zucca E.
2017 The Lancet Haematology Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Carlo Visco, Annalisa Chiappella, Luca Nassi, Caterina Patti, Simone Ferrero, Daniela Barbero, Andrea Evangelista, Michele Spina, Annalia Molinari, Luigi Rigacci, Monica Tani, Alice Di Rocco, Graziella Pinotti, Alberto Fabbri, Renato Zambello, Silvia Finotto, Manuel Gotti, Angelo M Carella, Flavia Salvi, Stefano A Pileri, Marco Ladetto, Giovannino Ciccone, Gianluca Gaidano, Marco Ruggeri, Maurizio Martelli, Umberto Vitolo
2017 American Journal of Hematology CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell AQ1 lymphoma: Possible biomarkers for novel targeted therapies? Francesco Zaja, Valentina Tabanelli, Claudio Agostinelli, Angelica Calleri, Annalisa Chiappella, Marzia Varettoni, Pier Luigi Zinzani, Stefano Volpetti, Elena Sabattini, Renato Fanin, Stefano Aldo Pileri
2016 British journal of haematology Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Zallio F., Tamiazzo S., Monagheddu C., Merli F., Ilariucci F., Stelitano C., Liberati AM., Mannina D.,Vitolo U., Angelucci E., Rota Scalabrini D., Vallisa D., Bellei M., Bari A., Ciccone G., Salvi F., Levis A.
2016 Haematologica Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Luminari S1, Galimberti S2, Versari A3, Biasoli I4, Anastasia A5, Rusconi C6, Ferrari A7, Petrini M2, Manni M8, Federico M8.
2016 Leukemia & lymphoma A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. Luminari S1, Goldaniga M2, Cesaretti M1, Orsucci L3, Tucci A4, Pulsoni A5, Salvi F6, Arcaini L7, Carella AM8, Tedeschi A9, Pinto A10, Stelitano C11, Baldini L2.
2016 Haematologica Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Sacchi S., Marcheselli R., Bari A., Buda G., Molinari AL., Baldini L., Vallisa D., Cesaretti M., Musto P.,Ronconi S., Specchia G., Silvestris F., Guardigni L., Ferrari A, Chiapella A., Carella AM., Santoro A., Di Raimondo F., Marcheselli L., Pozzi S.
2016 Leukemia & lymphoma A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. Stefano Luminari, Maria Goldaniga, Marina Cesaretti, Lorella Orsucci, Alessandra Tucci, Alessandro Pulsoni, Flavia Salvi, Luca Arcaini, Angelo Michele Carella, Alessandra Tedeschi, Antonello Pinto, Caterina Stelitano and Luca Baldini
2016 Leukemia & lymphoma B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of theFondazione Italiana Linfomi (FIL). Balzarotti M1, Brusamolino E1,2, Angelucci E3, Carella AM4, Vitolo U5, Russo E6, Congiu A4, Gotti M2, Massidda S3, Botto B5, Annechini G6, Spina M7, Re A8, Zilioli VR9, Merli F10, Salvi F11, Stelitano C12, Bonfichi M2, Rodari M1, Murru R3, Magagnoli M1, Anastasia A1,8, Mazza R1, Giordano L1,Santoro A1,13.
2016 Journal of clinical oncology Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. Zinzani PL1, Broccoli A2, Gioia DM2, Castagnoli A2, Ciccone G2, Evangelista A2, Santoro A2, Ricardi U2, Bonfichi M2, Brusamolino E2, Rossi G2, Anastasia A2, Zaja F2, Vitolo U2, Pavone V2, Pulsoni A2, Rigacci L2, Gaidano G2, Stelitano C2, Salvi F2, Rusconi C2, Tani M2, Freilone R2, Pregno P2, Borsatti E2,Sacchetti GM2, Argnani L2, Levis A2.
2016 Leukemia & lymphoma Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy Patrizia Ciammella, Andrea Riccardo Filippi, Gabriele Simontacchi, Michela Buglione, Carlo Furlan, Michele Spina, Alessandra Tucci, Luigi Rigacci, Cinzia Iotti, Umberto Vitolo, Umberto Ricardi and Francesco Merli
2016 British journal of haematology Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Patrizia Ciammella, Andrea Riccardo Filippi, Gabriele Simontacchi, Michela Buglione, Barbara Botto, Monica Mangoni, Cinzia Iotti, Francesco Merli, Luigi Marcheselli, Gianni Bisi, Umberto Ricardi and Annibale Versari
2016 The Lancet. Haematology Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).
2016 Thrombosis Research PO-03 – Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). Santi RM1, Ceccarelli M2, Catania G3, Monagheddu C2, Evangelista A4, Bernocco E5, Monaco F6, Federico M7, Vitolo U8,Cortelazzo S9, Cabras MG10, Spina M11, Baldini L12, Boccomini C13, Chiappella A14, Bari A15, Luminari S16, Calabrese M17, Levis A18, Visco C19, Contino L1, Ciccone G20, Ladetto M21.
2016 Journal of clinical oncology Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Merli F1, Luminari S2, Gobbi PG2, Cascavilla N2, Mammi C2, Ilariucci F2, Stelitano C2, Musso M2, Baldini L2, Galimberti S2, Angrilli F2, Polimeno G2, Scalzulli PR2, Ferrari A2, Marcheselli L2, Federico M2.
2016 Journal of hematology & oncology A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Pellegrini C, Dodero A, Chiappella A, Monaco F, Degl’Innocenti D, Salvi F, Vitolo U, Argnani L, Corradini P, Zinzani PL
2016 Future oncology ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Nowakowski GS, Chiappella A, Witzig TE, Spina M, Gascoyne RD, Zhang L, Flament J, Repici J, Vitolo U.
2016 Journal of clinical oncology Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis
2016 Physica Medica The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A.
2016 Haematologica Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Sacchi S, Marcheselli R, Bari A, Buda G, Molinari AL, Baldini L, Vallisa D, Cesaretti M, Musto P, Ronconi S, Specchia G, Silvestris F, Guardigni L, Ferrari A, Chiapella A, Carella AM, Santoro A, Di Raimondo F, Marcheselli L, Pozzi S.
2016 Leukemia & lymphoma The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Vitolo U.
2016 Journal of chemotherapy Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab. Cencini E, Guerrini S, Mazzei MA, Chiappella A, Fabbri A.
2016 Journal of clinical oncology Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Flavia Salvi, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, and Carmelo Carlo-Stella
2016 Hematological oncology Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. Ceriani L, Barrington S, Biggi A, Malkowski B, Metser U, Versari A, Martelli M, Davies A, Johnson PW, Zucca E, Chauvie S.
2016 International journal of radiation oncology, biology, physics PET/CT assessment after immunochemotherapy and irradiation using the Lugano Classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma L. Ceriani1, M. Martelli2, M.K. Gospodarowicz16, U. Ricardi, A.J.M. Ferreri4, U. Vitolo5, C. Stelitano6, M. Balzarotti, M.E. Cabrera, D.Cunningham, A. Guarini , P.L. Zinzani3, L. Giovanella1, P.W.M. Johnson17, and E. Zucca15.
2016 Journal of clinical oncology Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A.
2015 American journal of hematology The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi Rossi G1, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, Martinelli G, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M.
2015 Leukemia & lymphoma Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. Mannu C, Gazzola A, Ciabatti E, Fuligni F, Cavalli M, Della Starza I, Genuardi E, Mantoan B, Monitillo L, Del Giudice I, Ladetto M, Gaidano G, Sabattini E, Pileri SA, Galimberti S, Piccaluga PP; Fondazione Italiana Linfomi Minimal Residual Disease Network.
2015 Haematologica The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefitfrom doxorubicin: FIL-FOLL study. Rossi D1, Bruscaggin A1, La Cava P2, Galimberti S3, Ciabatti E3, Luminari S4, Rigacci L5, Tucci A6, Pulsoni A7, Bertoldero G8, Vallisa D9, Rusconi C10, Spina M11, Arcaini L12, Angrilli F13, Stelitano C14, Merli F15, Gaidano G1, Federico M4, Palumbo GA16
2015 Leukemia & lymphoma Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M; Italian Lymphoma Foundation (FIL).
2015 British journal of haematology Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Marcheselli L1, Bari A, Anastasia A, Botto B, Puccini B, Dondi A, Carella AM, Alvarez I, Chiarenza A, Arcari A, Salvi F, Federico M.
2015 American journal of hematology The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentricstudy by the fondazione italiana linfomi (FIL). Rigacci L1, Puccini B1, Zinzani PL2, Biggi A3, Castagnoli A4, Merli F5, Balzarotti M6, Stelitano C7, Spina M8, Vitolo U9, Stefoni V2, Levis A10, Gotti M11, Rosaria S12, Maria SP13, Bosi A1, Gallamini A14.
2015 Leukemia & lymphoma Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione ItalianaLinfomi phase II study. Iannitto E1, Luminari S2, Tripodo C3, Mancuso S1, Cesaretti M2, Marcheselli L2, Merli F4, Stelitano C5, Carella AM6, Fragasso A7, Montechiarello E5, Ricciuti G8, Pulsoni A9, Paulli M10, Franco V3, Federico M2.
2015 Oncologist Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Jackson AE, Mian M, Kalpadakis C, Pangalis GA, Stathis A, Porro E, Conconi A, Cortelazzo S, Gaidano G, Lopez Guillermo A, Johnson PW, Martelli M, Martinelli G, Thieblemont C, McPhail ED, Copie-Bergman C, Pileri SA, Jack A, Campo E, Mazzucchelli L, Ristow K, Habermann TM, Cavalli F, Nowakowski GS, Zucca E.
2015 Blood Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primarymediastinal (thymic) large B-cell lymphoma. Ceriani L1, Martelli M2, Zinzani PL3, Ferreri AJ4, Botto B5, Stelitano C6, Gotti M7, Cabras MG8, Rigacci L9, Gargantini L10, Merli F11, Pinotti G12, Mannina D13, Luminari S14, Stathis A1, Russo E2, Cavalli F1, Giovanella L1, Johnson PW15, Zucca E1.
2015 Practical radiation oncology Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. Piva C1, Genovesi D2, Filippi AR3, Balducci M4, Barra S5, Buglione M6, Busetto M7, Ciammella P8, Franzone P9, De Sanctis V10, Simontacchi G11, Fusella M12, Ricardi U1; Radiation Oncology Committee of the Italian Lymphoma Foundation (FIL).
2015 International journal of radiation oncology, biology, physics Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. In Reply to Adams and Kwee. Simontacchi G1, Filippi AR2, Ciammella P3, Ricardi U2.
2015 Journal of clinical oncology Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. Ferreri AJ1, Donadoni G2, Cabras MG2, Patti C2, Mian M2, Zambello R2, Tarella C2, Di Nicola M2, D’Arco AM2, Doa G2, Bruno-Ventre M2, Assanelli A2, Foppoli M2, Citterio G2, Fanni A2, Mulè A2, Caligaris-Cappio F2, Ciceri F2
2015 Leukemia & lymphoma Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R, Santagostino A, Ilariucci F, Carli G, Musto P, Savini P, Marino D, Ghio F, Gentile M, Cox MC, Vallisa D.
2014 Leukemia & lymphoma. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Merli F1, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A, Spina M, Tucci A, Stelitano C, Capodanno I, Fragasso A, Baldini L, Bottelli C, Montechiarello E, Fogazzi S, Lamorgese C, Cavalli L, Federico M; Fondazione Italiana Linfomi.
2014 Leukemia & lymphoma. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma heldin Menton, France, 3-5 October 2012. Meignan M1, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A.
2014 Annals of oncology The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subsetanalysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Luminari S1, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, Merli F, Spina M, Ferreri AJ, Zinzani PL, Gallamini A, Franceschetto A, Boccomini C, Franceschetti S, Salvi F, Raimondo FD, Carella AM, Micol Q, Balzarotti M, Musto P, Federico M
2014 The New England journal of medicine. The role of myeloablation for lymphoma. Schmitz N, Ziepert M, Vitolo U; German High-Grade Non-Hodgkin’s Lymphoma Study Group; Fondazione Italiana Linfomi.
2014 Haematologica Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi Merli M1, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D’Arco AM, Musto P, Chiappella A, Baldini L, Bonfichi M, Arcaini L.
2014 Journal of clinical oncology Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkinlymphoma is associated with an increased risk of early relapse: Clinical results of the preplannedinterim analysis of the randomized EORTC/LYSA/FIL H10 trial. Raemaekers JM1, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C.
2014 The Lancet Oncology Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Vitolo U1, Chiappella A2, Franceschetti S3, Carella AM4, Baldi I5, Inghirami G6, Spina M7, Pavone V8, Ladetto M9, Liberati AM10, Molinari AL11, Zinzani P12, Salvi F13, Fattori PP14, Zaccaria A15, Dreyling M16, Botto B2, Castellino A2, Congiu A4, Gaudiano M6, Zanni M9, Ciccone G17, Gaidano G3, Rossi G18; Fondazione Italiana Linfomi.
2014 Journal of clinical oncology [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. Martelli M1, Ceriani L1, Zucca E2, Zinzani PL1, Ferreri AJ1, Vitolo U1, Stelitano C1, Brusamolino E1, Cabras MG1, Rigacci L1, Balzarotti M1, Salvi F1, Montoto S1, Lopez-Guillermo A1, Finolezzi E1, Pileri SA1, Davies A1, Cavalli F1, Giovanella L1, Johnson PW1.
2014 Annals of oncology Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi Arcaini L1, Vallisa D2, Rattotti S3, Ferretti VV3, Ferreri AJ4, Bernuzzi P2, Merli M5, Varettoni M3, Chiappella A6, Ambrosetti A7, Tucci A8, Rusconi C9, Visco C10, Spina M11, Cabras G12, Luminari S13, Tucci M14, Musto P15, Ladetto M16, Merli F17, Stelitano C18, d’Arco A19, Rigacci L20, Levis A21, Rossi D22, Spedini P23, Mancuso S24, Marino D25, Bruno R26, Baldini L27, Pulsoni A28.
2014 British journal of haematology Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi Anastasia, A., Carlo-Stella, C., Corradini, P., Salvi, F., Rusconi, C., Pulsoni, A., Hohaus, S., Pregno, P., Viviani, S., Brusamolino, E., Luminari, S., Giordano, L., and Santoro A.
2014 Leukemia Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosedpatients with peripheral T-cell lymphoma. Corradini P1, Vitolo U2, Rambaldi A3, Miceli R4, Patriarca F5, Gallamini A6, Olivieri A7, Benedetti F8, Todeschini G8, Rossi G9, Salvi F10, Bruno B2, Baldini L11, Ferreri A12, Patti C13, Tarella C14, Pileri S15, Dodero A16.
2014 Journal of clinical oncology Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute.
2014 Journal of geriatric oncology The “Elderly Project” by The Fil (Fondazione Italiana Linfomi): A project aimed at the prospective multidimensional assessment of elderly patients with diffuse large B-cell lymphoma F. Merli, S. Luminari, A. Tucci, C. Mammi, M. Balzarotti, G. Cabras, F. Angrilli, A. Fabbri, I. Alvarez, M. Spina
2014 Leukemia & lymphoma Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173patients by the Lymphoma Italian Foundation (FIL). Tucci A1, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M; Italian Lymphoma Foundation (FIL).
2014 Clinical cancer research Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Galimberti S1, Luminari S2, Ciabatti E3, Grassi S4, Guerrini F4, Dondi A2, Marcheselli L2, Ladetto M5, Piccaluga PP6, Gazzola A6, Mannu C6, Monitillo L5, Mantoan B5, Del Giudice I7, Della Starza I7, Cavalli M7, Arcaini L8, Tucci A9, Palumbo GA10, Rigacci L11, Pulsoni A7, Vitolo U5, Boccomini C5, Vallisa D12, Bertoldero G13, Gaidano G14, Musto P15, Petrini M4, Federico M2.